What is the recommended treatment for a vaginal Mycoplasma genitalium infection in an adult woman?

Treatment of Vaginal Mycoplasma genitalium Infection

For a vaginal Mycoplasma genitalium infection in an adult woman, treat with doxycycline 100 mg orally twice daily for 7 days followed immediately by azithromycin 1 g orally on day 1, then 250 mg daily on days 2–5. 1, 2

First-Line Treatment Approach

The 2-step sequential regimen is now standard because it addresses the high rates of macrolide resistance that have emerged globally:

• Doxycycline 100 mg orally twice daily for 7 days reduces the organism load and decreases the risk of selecting macrolide-resistant strains during subsequent azithromycin therapy 1
• Azithromycin 500 mg on day 1, followed by 250 mg daily on days 2–5 (extended 5-day regimen) achieves 85–95% cure rates for macrolide-susceptible infections 1
• The extended azithromycin regimen is superior to the older 1 g single-dose protocol, which is no longer recommended 3

This sequential approach is critical because doxycycline monotherapy cures only 30–40% of M. genitalium infections, while azithromycin alone (without doxycycline pretreatment) increases the risk of inducing macrolide resistance 1, 3

When to Use Moxifloxacin Instead

If macrolide resistance is documented or suspected (prior azithromycin failure), use moxifloxacin 400 mg orally once daily for 7 days for uncomplicated infection 1, 2

• Moxifloxacin achieves 82% microbiologic cure compared to 41% with azithromycin regimens in real-world settings 4
• Treatment with moxifloxacin is associated with 4 times the odds of microbiologic cure relative to low-dose azithromycin (adjusted OR 4.18,95% CI 1.73–10.13) 4
• However, fluoroquinolone resistance is increasing, and moxifloxacin carries FDA black-box warnings for serious adverse effects (tendon rupture, peripheral neuropathy, CNS effects), so reserve it for documented macrolide resistance or treatment failures 1, 3

Resistance-Guided Therapy (Ideal but Often Unavailable)

• Macrolide resistance testing should ideally guide treatment, as more than 50% of M. genitalium infections are now macrolide-resistant 5, 1
• A strong and consistent association exists between 23S rRNA gene mutations and azithromycin treatment failure 3
• However, FDA-approved resistance tests are not widely available in the United States, so empiric treatment is often necessary 2

Partner Management

• Treat all sexual partners from the preceding 60 days simultaneously with the same regimen, regardless of symptoms 6
• Partners should be treated even if asymptomatic to prevent reinfection 6
• Both patient and partners must abstain from all sexual intercourse until both have completed treatment and are asymptomatic 6
• Inadequate partner treatment is the most common cause of recurrent infection 6

Follow-Up and Test-of-Cure

• Do not perform routine test-of-cure in asymptomatic patients after treatment 5
• If symptoms persist after treatment, re-test for M. genitalium and evaluate for other pathogens 6
• Assess for possible reinfection from untreated partners if symptoms recur 6
• Nucleic acid amplification testing (NAAT) is the only diagnostic method; culture is not available 5, 1

Clinical Presentations to Recognize

• Women with M. genitalium most commonly present with vaginal discharge (45% of cases) 4
• M. genitalium is associated with cervicitis and pelvic inflammatory disease in 10–25% of infected women 1
• The organism contributes to 10–35% of non-chlamydial non-gonococcal urethritis in men 1
• Asymptomatic infections are frequent, but testing is not recommended in asymptomatic individuals without known exposure 2

Critical Pitfalls to Avoid

• Never use azithromycin 1 g single dose alone—this outdated regimen has poor efficacy and drives macrolide resistance 3
• Never skip the doxycycline pretreatment step when using azithromycin, as this increases resistance selection 1
• Do not use moxifloxacin as first-line therapy unless macrolide resistance is documented, given its adverse effect profile and the need to preserve fluoroquinolone efficacy 1, 2
• Incomplete treatment courses lead to persistent infection and resistance development 6
• Always treat partners concurrently—failure to do so results in reinfection rates up to 20% 6

Third-Line Options for Multidrug-Resistant Infections

If both azithromycin and moxifloxacin fail:

• Doxycycline or minocycline 100 mg twice daily for 14 days may cure 40–70% 1
• Pristinamycin 1 g four times daily for 10 days has a cure rate around 75%, but availability is limited 1
• Cases of coexistent macrolide and fluoroquinolone resistance have been documented, threatening future treatment options 3

Special Considerations for Pregnancy

• Azithromycin is the only safe first-line option in pregnancy; all guidelines recommend it 7
• Moxifloxacin is contraindicated in pregnancy 7
• Dosing schedules for azithromycin in pregnancy vary between guidelines, but the extended 5-day regimen (500 mg day 1, then 250 mg days 2–5) is most commonly recommended 7
• Safety data for pristinamycin in pregnancy is inconsistent and insufficient 7